LGMN and hematopoietic and lymphoid cell neoplasm: Recent findings show that Lgmn cleaves PAR2 at the N<sub>30</sub>-R<sub>31</sub> residue, a site also targeted by L-asparaginase, a vital treatment for acute lymphoblastic leukemia (ALL), a severe hematologic cancer that poses high risks to children.